For nonsmokers with amnestic mild cognitive impairment (MCI), use of a transdermal nicotine patch for six months is associated with improved cognitive test performance, but not clinical global impression of change.
Baxter International announced that it has submitted a supplemental Biologics License Application (sBLA) for Gammagard Liquid 10% [immune globulin infusion (human)] for the treatment of multifocal motor neuropathy (MMN).
Curemark announced results from its Phase 3 study of CM-AT for the treatment of autism in children 3 to 8 years of age.
Cuvposa (glycopyrrolate liquid; Shionogi) has been made available for the treatment of chronic severe drooling associated with neurologic conditions (eg, cerebral palsy) in patients 3-16 years of age.
BrainStorm was granted orphan drug designation by the FDA for its drug candidate, NurOwn, an autologous adult stem cell product for the treatment of ALS, or Lou Gehrig’s Disease.
Avanir announced that Nuedexta (dextromethorphan hydrobromide and quinidine sulfate capsules) is now available for the treatment of pseudobulbar affect.
Medivation announced that patient enrollment was completed for its Phase 3 clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) evaluating the potential efficacy of Dimebon when added to ongoing treatment with donepezil.
Teva and Active Biotech announced initial results from their Phase 3 trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (MS).
Alexion announced that results from its Phase 2 study of Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy.
Avanir Pharmaceuticals announced that the FDA has approved Nuedexta (dextromethorphan hydrobromide and quinidine sulfate capsules) for the treatment of pseudobulbar affect (PBA).
